<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741517</url>
  </required_header>
  <id_info>
    <org_study_id>PRORESS pancreas</org_study_id>
    <nct_id>NCT03741517</nct_id>
  </id_info>
  <brief_title>Biomarker Study of Pancreatic Neuroendocrine Tumours</brief_title>
  <official_title>Prospective Longitudinal Observation Trial of Clinical and Molecular Features of Pancreatic Neuroendocrine Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The biology of pancreatic neuroendocrine tumors can change during the disease course. This
      evolution of disease can manifest through increases in tumor proliferation rate, resistance
      to medical therapy and/or a change in tumor hormone secretion. This study aims to
      characterize how the biology of pancreatic neuroendocrine tumors change over time, measured
      by; patient symptoms, biochemistry, contrast enhanced computed tomography, DOTATOC-PET,
      FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell
      differentiation). Uptake on 68Ga-DOTATOC and 18F-FDG-PET will be correlated directly to tumor
      cell proliferation rate. Fraction of patients with spatial heterogeneity in DOTATOC as well
      as FDG uptake as well as metachronous changes in all collected data will be documented.
      Biomaterial from whole blood and core needle biopsies will be characterized on the molecular
      level, and those findings will be integrated to the above specified clinical parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Protocol adherence</measure>
    <time_frame>Study inclusion</time_frame>
    <description>Defined as the proportion of patients where that following investigations are performed: Core needle biopsy, FDG-PET, DOTATOC-PET, research blood samples, pancreatic hormones and hormonal syndromes.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety of core needle biopsy: NCI Common Terminology Criteria</measure>
    <time_frame>At study inclusion and within 48 hours of the procedure</time_frame>
    <description>Defined as a NCI Common Terminology Criteria for Adverse Events 4.03 grade 3-4 adverse event related to the procedure.</description>
  </other_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Neuroendocrine Tumor</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG-PET</intervention_name>
    <description>Fludeoxyglucose F18</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>68Ga-DOTATOC-PET</intervention_name>
    <description>DOTA-tyr3-Octreotide Ga68</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Computed tomography</intervention_name>
    <description>Computed tomography of thorax and abdomen with 3-phase contrast</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Core needle biopsy</intervention_name>
    <description>Core needle biopsy of metastatic lesions</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>Phlebotomy from peripheral vein</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pancreatic Neuroendocrine Tumors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  Informed consent

          -  Pathology confirmed diagnosis of pancreatic neuroendocrine tumor WHO grade 1-3 or
             neuroendocrine carcinoma grade 3.

        Exclusion Criteria:

          -  Patient does not consent

          -  Pregnancy or no contraceptive in fertile women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joakim Crona, MD, PhD</last_name>
    <phone>0046186110000</phone>
    <email>joakim.crona@medsci.uu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joakim Crona, MD PhD</last_name>
      <phone>+46186110000</phone>
      <email>joakim.crona@medsci.uu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Joakim Crona</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

